Valuation: Natera, Inc.

Capitalization 28.2B 24.16B 22.09B 20.92B 38.73B 2,696B 39.04B 264B 102B 1,281B 106B 104B 4,460B P/E ratio 2026 *
-120x
P/E ratio 2027 * -570x
Enterprise value 27.18B 23.28B 21.29B 20.16B 37.33B 2,599B 37.63B 254B 98.69B 1,235B 102B 99.82B 4,298B EV / Sales 2026 *
9.74x
EV / Sales 2027 * 8.16x
Free-Float
96.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.81%
1 week-10.42%
Current month-4.49%
1 month-8.26%
3 months-4.52%
6 months-3.61%
Current year-14.05%
1 week 190.57
Extreme 190.57
206
1 month 189.53
Extreme 189.53
221.56
Current year 181
Extreme 181
256.36
1 year 131.81
Extreme 131.8106
256.36
3 years 36.9
Extreme 36.9
256.36
5 years 26.1
Extreme 26.1
256.36
10 years 7.35
Extreme 7.35
256.36
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2019-12-31
Director of Finance/CFO 46 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Change 5d. change 1-year change 3-years change Capi.($)
+0.81%-10.42%+30.11%+285.34% 28.2B
+1.19%-1.11%-28.78%-48.32% 6.61B
+0.85%-7.08%-11.45%+98.04% 4.2B
+0.25%-2.61%+15.06%+59.96% 2.8B
-2.78%-5.47%-18.60%-65.21% 1.79B
-7.06%-8.15%+20.17%-28.46% 1.7B
+0.38%-1.78%+25.97%+0.77% 1.74B
+1.58%+0.88%+44.77%+244.10% 1.37B
-1.33%+6.94%+33.96%+60.06% 1.17B
-0.23%-4.07%-34.65%+464.27% 1.15B
Average -0.62%-3.62%+7.66%+107.05% 5.07B
Weighted average by Cap. +0.38%-7.06%+14.99%+179.04%

Financials

2026 *2027 *
Net sales 2.79B 2.39B 2.19B 2.07B 3.83B 267B 3.86B 26.09B 10.13B 127B 10.47B 10.25B 441B 3.3B 2.82B 2.58B 2.45B 4.53B 315B 4.56B 30.81B 11.97B 150B 12.37B 12.11B 521B
Net income -219M -188M -171M -162M -301M -20.93B -303M -2.05B -795M -9.95B -822M -804M -34.62B -43.87M -37.59M -34.37M -32.55M -60.25M -4.2B -60.74M -410M -159M -1.99B -165M -161M -6.94B
Net Debt -1.02B -875M -800M -758M -1.4B -97.64B -1.41B -9.55B -3.71B -46.4B -3.83B -3.75B -161B -1.3B -1.11B -1.02B -964M -1.78B -124B -1.8B -12.15B -4.72B -59.04B -4.88B -4.77B -205B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-05-14 196.91 $ +0.81% 1,382,251
26-05-13 195.32 $ -4.35% 1,664,304
26-05-12 204.21 $ +2.55% 1,566,969
26-05-11 199.14 $ +2.52% 2,041,865
26-05-08 194.24 $ -11.64% 3,925,677
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
196.91USD
Average target price
260.89USD
Spread / Average Target
+32.49%

Quarterly revenue - Rate of surprise